Wedbush Keeps Price Targets on Telix and Xencor at $22 and $30 a Share
Dow Jones Newswires reported that Wedbush kept its price target at $22 a share for Telix Pharmaceuticals and $30 for Xencor. Both calls were published October 21, 2026.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Dow Jones Newswires, Wedbush analysts maintained their price target on Telix Pharmaceuticals shares at $22.00 per share.
Separately, Wedbush confirmed its price target on Xencor shares at $30.00 per share. Both updates were published on October 21, 2026.
why it matters
Reiterating an unchanged price target usually does not immediately alter a stock's valuation, so such notes draw only modest attention from investors. Full ratings details are available in Benzinga's analyst section.
market impact
Telix and Xencor shares: reiterated price targets may modestly affect investor sentiment
tags
instruments
sources
- Telix Pharmaceuticals Price Target Maintained With a $22.00/Share by Wedbush — Dow Jones Newswires, 21 October 2026 at 13:11 UTC
- Xencor Price Target Maintained With a $30.00/Share by Wedbush — Dow Jones Newswires, 21 October 2026 at 13:10 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗